ChiCTR2500111406 版本V1.0 版本创建时间2025/10/30 17:05:35 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500111406 

最近更新日期:

Date of Last Refreshed on:

2025-10-30 17:05:29 

注册时间:

Date of Registration:

2025-10-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

动态血糖参数与糖尿病肾病肾功能指标的相关性分析

Public title:

Analysis of the Correlation between Dynamic Glycemic Parameters and Renal Function Markers in Diabetic Kidney Disease.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

动态血糖参数与糖尿病肾病肾功能指标的相关性分析

Scientific title:

Analysis of the Correlation between Dynamic Glycemic Parameters and Renal Function Markers in Diabetic Kidney Disease.

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杭嘉吉 

研究负责人:

杭嘉吉 

Applicant:

Hang Jiaji 

Study leader:

Hang Jiaji 

申请注册联系人电话:

Applicant telephone:

+86 157 5115 9060

研究负责人电话:

Study leader's
telephone:

+86 514 8098 1199

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1627699789@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1627699789@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省扬州市邗江中路368号

研究负责人通讯地址:

江苏省扬州市邗江中路368号

Applicant address:

No. 368, Hanjiang Middle Road, Yangzhou City, Jiangsu Province

Study leader's address:

No. 368, Hanjiang Middle Road, Yangzhou City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

扬州大学附属医院

Applicant's institution:

Affiliated Hospital of Yangzhou University

研究负责人所在单位:

扬州大学附属医院

Affiliation of the Leader:

Affiliated Hospital of Yangzhou University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-YKL07-K03

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

扬州大学附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of Affiliated Hospital of Yangzhou University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-07-17 00:00:00

伦理委员会联系人:

许冰菊

Contact Name of the ethic committee:

Xu Bingju

伦理委员会联系地址:

扬州大学附属医院西区医院行政楼508会议室

Contact Address of the ethic committee:

Room 508, Administrative Building, West Campus Hospital, Yangzhou University Affiliated Hospital

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 514 8031 9670

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

扬州大学附属医院

Primary sponsor:

Affiliated Hospital of Yangzhou University

研究实施负责(组长)单位地址:

江苏省扬州市邗江中路368号

Primary sponsor's address:

No. 368, Hanjiang Middle Road, Yangzhou City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

扬州大学附属医院

具体地址:

江苏省扬州市邗江中路368号

Institution
hospital:

Affiliated Hospital of Yangzhou University

Address:

No. 368, Hanjiang Middle Road, Yangzhou City, Jiangsu Province

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected research topic (self-funded)

研究疾病:

糖尿病  

Target disease:

Diabetes

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

本研究通过动态血糖监测(CGM)参数与2型糖尿病(T2DM)患者糖尿病肾病(DKD)相关指标的关系探究,旨在为临床管理提供依据。  

Objectives of Study:

This study investigates the relationship between continuous glucose monitoring (CGM) parameters and indicators associated with diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM), aiming to provide evidence for clinical management.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

所有患者均符合1999年WHO糖尿病诊断标准,且DKD诊断标准参照2017年版《中国2型糖尿病防治指南》诊断标准,确诊为糖尿病发生后出现的肾病或糖尿病肾病,临床症状体征符合DKD表现。

Inclusion criteria

All patients met the 1999 WHO diagnostic criteria for diabetes mellitus. The diagnosis of diabetic kidney disease (DKD) was based on the 2017 Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes, confirming the presence of kidney disease or diabetic nephropathy following the diagnosis of diabetes. Clinical symptoms and signs were consistent with DKD manifestations.

排除标准:

3个月内发生严重糖尿病并发症者;妊娠及哺乳期患者;合并严重感染、恶性肿瘤、急性心力衰竭、急性脑卒中者。

Exclusion criteria:

Patients who have experienced severe diabetic complications within the past three months; pregnant or lactating patients; patients with concurrent severe infections, malignant tumors, acute heart failure, or acute stroke.

研究实施时间:

Study execute time:

From 2025-11-03 00:00:00 To 2025-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-11-03 00:00:00 To 2025-12-01 00:00:00

干预措施:

Interventions:

组别:

合并DKD组

样本量:

170

Group:

Combined DKD group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

未合并DKD组

样本量:

125

Group:

The DKD group was not combined

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

扬州大学附属医院 

单位级别:

三甲 

Institution
hospital:

Affiliated Hospital of Yangzhou University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

葡萄糖波动的平均幅度

指标类型:

次要指标

Outcome:

Mean amplitude of glucose fluctuation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日内平均糖波动幅度

指标类型:

次要指标

Outcome:

Mean Amplitude of Glycemic Excursions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日内最大糖波动幅度

指标类型:

次要指标

Outcome:

Maximum Blood Glucose Excursion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日均血糖值

指标类型:

次要指标

Outcome:

Average Daily Blood Glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日内血糖标准差

指标类型:

次要指标

Outcome:

Within-day Standard Deviation of Blood Glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血糖变异系数

指标类型:

次要指标

Outcome:

Fasting Blood Glucose Coefficient of Variation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

葡萄糖目标范围内时间

指标类型:

次要指标

Outcome:

Time in Range

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血尿酸

指标类型:

次要指标

Outcome:

Serum Uric Acid

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血肌酐

指标类型:

次要指标

Outcome:

Serum Creatinine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总胆红素

指标类型:

次要指标

Outcome:

Serum Total Bilirubin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

直接胆红素

指标类型:

次要指标

Outcome:

Direct Bilirubin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

间接胆红素

指标类型:

次要指标

Outcome:

Indirect Bilirubin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

丙氨酸氨基转移酶

指标类型:

次要指标

Outcome:

Alanine Aminotransferase

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

草酰乙酸氨基转移酶

指标类型:

次要指标

Outcome:

Aspartate Aminotransferase

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

γ-谷氨酰转移酶

指标类型:

次要指标

Outcome:

Gamma-Glutamyl Transferase

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总胆固醇

指标类型:

次要指标

Outcome:

Total Cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甘油三酯

指标类型:

次要指标

Outcome:

Triglycerides

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白胆固醇

指标类型:

次要指标

Outcome:

Low-Density Lipoprotein Cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高密度脂蛋白胆固醇

指标类型:

次要指标

Outcome:

High-Density Lipoprotein Cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

载脂蛋白 A1

指标类型:

次要指标

Outcome:

Apolipoprotein A1

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

载脂蛋白 B

指标类型:

次要指标

Outcome:

Apolipoprotein B

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹胰岛素

指标类型:

次要指标

Outcome:

Fasting Insulin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血糖

指标类型:

次要指标

Outcome:

Fasting Plasma Glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖化血清蛋白

指标类型:

次要指标

Outcome:

Glycated Albumin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹 C 肽

指标类型:

次要指标

Outcome:

Fasting C-Peptide

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

餐后2小时 C 肽

指标类型:

次要指标

Outcome:

2-Hour Postprandial C-Peptide

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿白蛋白蛋/肌酐比值

指标类型:

主要指标

Outcome:

Urine Albumin-to-Creatinine Ratio

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

估算肾小球滤过率

指标类型:

主要指标

Outcome:

Estimated Glomerular Filtration Rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-10-30 17:05:29